Prescription medicine
Natamycin Brand names: Natacyn
Natamycin (Natacyn) is a prescription medicine with an FDA approval on record since 1978. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the natamycin FDA label on DailyMed (effective October 30, 2025, Harrow Eye, LLC); the NDA 50514 record on Drugs@FDA; every natamycin label on DailyMed.
Highlights of the record
FDA label of October 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageNATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis.
Forms and strengths
- 50 mg/ml
Suspension/ drops.
On the market
- Earliest approval on file
- October 30, 1978 Natacyn, Harrow Eye; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 398 through July 30, 2026
What is natamycin used for?
From the label: indications and usageNATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.
Conditions named in the indications of natamycin's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Polyene Antimicrobial.
Source: FDA drug label (NATACYN), Harrow Eye, LLC, effective October 30, 2025 (SPL set 20ede08c-0d39-dc65-e063-6394a90aa3e0), via openFDA; the full label on DailyMed
Is there a generic for natamycin (Natacyn)?
No generic natamycin is approved (Drugs@FDA, October 8, 2026).
- 1978 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for natamycin?
The FDA Adverse Event Reporting System holds 398 reports that list natamycin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 88 are coded as a death and 150 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Natamycin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other